Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Canadian device user fees would take effect Sept. 1 under proposed reg.

This article was originally published in The Gray Sheet

Executive Summary

CANADIAN DEVICE PREMARKET SUBMISSIONS EXPECTED TO DROP AS MUCH AS 41.7% for "Part V" products following implementa-tion of a device user fee program, according to an economic impact study commissioned by Canada's Medical Devices Bureau (MDB) and conducted by Armar International. According to the study, which surveyed Canadian device manufacturers, the average decrease in premarket submissions and supplements under Part V of Canadian device law could be "as high as" 41.7% due to user fee expenses. MDB typically receives about 240 Part V submission a year; a 41.7% drop would reduce the number to 101.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT004237

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel